MedTrace Logo

Mitochondria in HIV and Aging (MITO+)

NCT03489421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2019-09-26

No results posted yet for this study

Summary

Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy. This dysfunction in mitochondria may lead to symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI). Furthermore, the investigators hypothesize that the older antiretroviral therapy (ART) of tenofovir disoproxil fumarate (TDF) is associated with greater impairment in mitochondrial function than the newer agent, tenofovir alafenamide (TAF).

Conditions

  • Human Immunodeficiency Virus (HIV)
  • Mitochondrial Diseases

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-15
Primary Completion
2019-09-05
Completion
2019-09-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03489421 on ClinicalTrials.gov